megestrol acetate + rosuvastatin

Megestrol acetate + rosuvastatin is a combination therapy being investigated by the Obstetrics and Gynecology Hospital of Fudan University for fertility-preserving treatment in young women with atypical endometrial hyperplasia (AEH) and dyslipidemia. The regimen consists of megestrol acetate, a synthetic progestational agent that acts as a progesterone receptor agonist to induce endometrial differentiation and reverse hyperplasia, and rosuvastatin, a small molecule statin that inhibits HMG-CoA reductase to lower cholesterol levels. This combination is based on the rationale that dyslipidemia is prevalent in AEH patients and that managing metabolic health with rosuvastatin can improve the clinical efficacy of progestin therapy, offering a potential fertility-sparing alternative to hysterectomy.

Brand names

Crestor

Other names

Megestrol acetate plus rosuvastatin